SciBase Initiates Sales Collaboration in Italy
SciBase Initiates Sales Collaboration in Italy
"I am really very proud to be part of a lifesaving project to address the critical issue of melanoma in STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announces today the collaboration with Kilabs srl, an Italian Company with expertise in dermatology, which now will be able to offer access to better diagnostics of skin cancer in Italy.
斯德哥爾摩，2024年10月30日 /PRNewswire/ — 基於增強智能的皮膚病解決方案的領先開發商SciBase Holding Ab（「SciBase」）（STO：SCIB）今天宣佈與具有皮膚病學專業知識的意大利公司Kilabs srl合作，該公司現在將能夠在意大利提供更好的皮膚癌診斷。
Kilabs is dedicated to advancing research, development and access to cutting-edge solutions in specialized medical fields. SciBase will adapt Nevisense for the Italian market, which is a regulatory prerequisite for the launch which is expected to take place in the first half of 2025. However, Kilabs will already now start preparing the market ahead of the planned launch. Skin cancer is a growing problem in Italy and access to Nevisense will significantly increase the possibility of early detection and improved care. Data in Italy show that mortality has increased, particularly among men.
Kilabs致力於推進專業醫療領域的研究、開發和尖端解決方案的獲取。SciBase將調整Nevisense以適應意大利市場，這是預計於2025年上半年推出的監管先決條件。但是，在計劃發佈之前，Kilabs現在已經開始爲市場做準備。皮膚癌在意大利是一個日益嚴重的問題，獲得Nevisense的機會將大大增加早期發現和改善護理的可能性。意大利的數據顯示，死亡率有所上升，尤其是男性。
Michelangelo Simonelli, CEO at Kilabs, is spearheading the introduction of Nevisense in Italy Under Simonelli's leadership leveraging on a team of recognized experts in the field such as Alessandro Cappella and Giuseppe Romano, Kilabs is working to integrate Nevisense into clinical practice, offering a more accurate and non-invasive method for early melanoma detection, which could significantly improve patient outcomes in the field of dermatology. This initiative underscores Kilabs' commitment to innovation and improving healthcare standards in Italy.
Kilabs首席執行官米開朗基羅·西蒙內利正在帶頭在意大利推出Nevisense。在西蒙內利的領導下，Kilabs利用亞歷山德羅·卡佩拉和朱塞佩·羅曼諾等該領域的知名專家團隊，正在努力將Nevisense整合到臨床實踐中，爲早期黑色素瘤檢測提供一種更準確、更無創的方法，這可能會顯著改善皮膚病領域的患者預後。該計劃凸顯了Kilabs對創新和改善意大利醫療保健標準的承諾。
"I am really very proud to be part of a lifesaving project to address the critical issue of melanoma in Italy. I firmly believe Kilabs will play a crucial role in securing appropriate deployment of Nevisense thanks to our high expertise and introduction in the field," says Michelangelo Simonelli CEO of Kilabs Srl.
「能參與一項旨在解決意大利黑色素瘤的關鍵問題的救生項目，我感到非常自豪。我堅信，得益於我們在該領域的豐富專業知識和介紹，Kilabs將在確保Nevisense的適當部署方面發揮至關重要的作用。」 Kilabs Srl首席執行官米開朗基羅·西蒙內利說。
"I look forward to a very exciting collaboration. During the year, we have met with Italian doctors and tested the interest in the technology together with our partner, and I look forward to being able to offer patients in Italy better diagnostics and care together with Kilabs. Kilabs will start preparing the market now to be ready to launch Nevisense when the regulatory adjustments are in place. We will thus be able to give more patients access to Nevisense," says Pia Renaudin, CEO of SciBase.
「我期待着一次非常激動人心的合作。在這一年中，我們與意大利醫生會面，並與我們的合作伙伴一起測試了人們對這項技術的興趣，我期待能夠與Kilabs一起爲意大利的患者提供更好的診斷和護理。Kilabs現在將開始爲市場做準備，以便在監管調整出臺後爲推出Nevisense做好準備。因此，我們將能夠讓更多的患者獲得Nevisense。」 SciBase首席執行官皮亞·雷諾丁說。
For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
如需更多信息，請聯繫：
首席執行官皮亞·雷諾丁，電話：+46732069802，電子郵件：[email protected]
認證顧問 (CA)：
卡內基投資銀行 Ab（publ）
電話：+46 (0) 73 856 42 65
電子郵件：[電子郵件保護]
About SciBase
關於 SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
SciBase 是一家全球醫療技術公司，專門從事皮膚病學的早期發現和預防。SciBase 開發並商業化了 Nevisense，這是一個獨特的即時護理平台，它結合了人工智能（人工智能）和先進的 EIS 技術，可提高診斷準確性，確保主動的皮膚健康管理。
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
我們的承諾是最大限度地減少患者的痛苦，使臨床醫生能夠通過及時的檢測和干預來改善和挽救生命，並降低醫療成本。
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SciBase建立在瑞典斯德哥爾摩卡羅林斯卡研究所20多年的研究基礎上，是皮膚病學進步領域的領導者。
About Kilabs
關於 Kilabs
Kilabs is an organization dedicated to advancing research, development and access to cutting-edge solutions in specialized medical fields.
Kilabs是一家致力於推進專業醫療領域尖端解決方案的研究、開發和獲取的組織。
This information was brought to you by Cision .
這些信息是由 Cision 帶給你的。
The following files are available for download:
以下文件可供下載：
|
PR Italy_PR eng final |
|
PR Italy_PR 英文決賽 |
